IgGenix
Latest round
- Series B
Last raised
- Feb 2023
Total raised
- $76M
Investors
- 6
About IgGenix
Founded in 2019 and headquartered in South San Francisco, US, IgGenix, Inc. specializes in developing therapies for allergies.IgGenix, Inc. specializes in the discovery and development of innovative monoclonal antibodies aimed at addressing allergies and other immunological diseases. Their core product, IGNX001, is an injectable allergen-specific therapeutic designed to block the allergic cascade, particularly focusing on peanut allergies. Utilizing the proprietary SEQ SIFTER™ antibody discovery platform, the company identifies rare IgE-producing human B cells, enabling the engineering of high-affinity, allergen-specific IgG antibodies.IgGenix's revenue model is based on clinical trial partnerships and research collaborations to advance their therapeutic offerings. The company works with healthcare institutions and pharmaceutical partners to develop product candidates like IGNX001, structured around research agreements and potential licensing deals. The company is focused on launching IGNX001 and aims to expand its reach into additional markets, specifically targeting regions with high incidences of allergic diseases.
Who invested in IgGenix
6 investors across 3 rounds
See all investors in IgGenix
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about IgGenix
Who invested in IgGenix?
IgGenix has 6 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has IgGenix raised?
IgGenix has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did IgGenix last raise money?
IgGenix's most recent round on record is a Series B, in Feb 2023.
What does IgGenix do?
Founded in 2019 and headquartered in South San Francisco, US, IgGenix, Inc.
Where is IgGenix headquartered?
IgGenix is headquartered in South San Francisco, US.
Which VCs invest in companies like IgGenix?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at IgGenix's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like IgGenix? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.